Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAmortizatization of IntangiblesAsset Writedowns and ImpairmentAsset Writedowns and ImpairmentCash from Financing ActivitiesCash from Financing ActivitiesCash from OperationsCash from OperationsChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in InventoryChange in ReceivablesChange in ReceivablesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsOther Working Capital ChangesOther Working Capital ChangesOther financing activitiesOther financing activitiesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

InMed Pharmaceuticals (INM) Cash from Financing Activities (2020 - 2026)

InMed Pharmaceuticals has reported Cash from Financing Activities over the past 5 years, most recently at -$137178.0 for Q3 2025.

  • For Q3 2025, Cash from Financing Activities fell 116.37% year-over-year to -$137178.0; the TTM value through Dec 2025 reached $11.0 million, up 831.0%, while the annual FY2025 figure was $12.3 million, 163.66% up from the prior year.
  • Cash from Financing Activities for Q3 2025 was -$137178.0 at InMed Pharmaceuticals, down from $8.2 million in the prior quarter.
  • Over five years, Cash from Financing Activities peaked at $10.9 million in Q3 2021 and troughed at -$836144.0 in Q4 2021.
  • A 5-year average of $2.9 million and a median of $838239.0 in 2024 define the central range for Cash from Financing Activities.
  • Biggest five-year swings in Cash from Financing Activities: crashed 117.31% in 2023 and later skyrocketed 4644531.25% in 2025.
  • Year by year, Cash from Financing Activities stood at -$836144.0 in 2021, then soared by 735.69% to $5.3 million in 2022, then tumbled by 101.2% to -$63697.0 in 2023, then soared by 631.46% to $338521.0 in 2024, then crashed by 140.52% to -$137178.0 in 2025.
  • Business Quant data shows Cash from Financing Activities for INM at -$137178.0 in Q3 2025, $8.2 million in Q2 2025, and $2.9 million in Q1 2025.